All News

Metformin hydrochloride extended-release tablets are indicated to for improving glycemic control in patients with type 2 diabetes mellitus, as an adjunct to diet and exercise.

The phase 3b/4 SPIRIT head-to-head study evaluated ixekizumab (Taltz) versus adalimumab (Humira) in psoriatic arthritis.

The FDA approved elexacaftor/tezacaftor/ivacaftor (Trikafta) earlier this month based on the results of a phase 3 clinical trial.

Riluzole oral film (Exservan, Aquestive Therapeutics) has received early-action approval from the FDA for the treatment of amyotrophic lateral sclerosis.

Managing elevated cholesterol is one of the the key elements to decreasing negative outcomes in atherosclerotic cardiovascular disease.

The FDA approved voxelotor (Oxbryta, Global Blood Therapeutics) tablets for the treatment of sickle cell disease in patients 12 years of age and older.

Amneal Pharmaceuticals has issued a voluntary recall of its ranitidine tablets, 150 mg and 300 mg, as well as ranitidine syrup (ranitidine oral solution, USP), 15 mg/mL.

A randomized clinical trial published by JAMA Internal Medicine found that the distribution of HIV self-tests is a useful source for increasing awareness of HIV infection, and for preventing future transmission, specifically among men having sex with men.

Why is a woman being prescribed phentermine for ADHD?

Approved by the FDA in May 2019, midazolam nasal spray CIV (Nayzilam, UCB) is the first nasal rescue treatment for seizure clusters in the United States.

Top news of the day from across the health care landscape.

The case study included a 45-year-old man diagnosed with stage 3 multiple myeloma who was treated with bortezomib and dexamethasone.

If approved, risdiplam (Genentech) would be the first at-home administered medicine for patients living with spinal muscular atrophy.

Jonathan Ogurchak, PharmD, CSP, sits down with Specialty Pharmacy Times to discuss how pharmacy schools can better prepare students for Specialty Pharmacy during the NASP Annual Meeting in Washington, DC.

The study evaluated the safety and efficacy of a live, attenuated zoster vaccine patients receiving tumor necrosis factor inhibitor therapies for various indications.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.